Q2 2025 · 13F-HR
ACORN CAPITAL ADVISORS, LLCholdings as filed
Filed 2025-08-14 · accession 0001636587-25-000043
$152.9M
Reported value
21
Positions
2025-06-30
Period end
The Brief · ACORN CAPITAL ADVISORS, LLC · Q2 2025
AI · grounded in 13F
ACORN CAPITAL ADVISORS, LLC established a new position in CGON valued at $29.4M. The fund also initiated new stakes in URGN for $17.3M and YMABUSD for $15.4M. Additional new positions include PBYI, CADL, and TRVI. The fund ended the period with 21 positions and total AUM of $152.9M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 156944100 | CGON | CG ONCOLOGY INC | $29.4M | 19.2% | 1,131,501 | Common | SOLE |
| M96088105 | URGN | UROGEN PHARMA LTD | $17.3M | 11.3% | 1,259,749 | Common | SOLE |
| 984241109 | YMABUSD | Y-MABS THERAPEUTICS INC | $15.4M | 10.1% | 3,418,995 | Common | SOLE |
| 74587V107 | PBYI | PUMA BIOTECHNOLOGY INC | $14.2M | 9.27% | 4,131,299 | Common | SOLE |
| 137404109 | CADL | CANDEL THERAPEUTICS INC | $13.1M | 8.54% | 2,580,517 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $11.7M | 7.67% | 2,144,844 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $7.4M | 4.81% | 1,971,264 | Common | SOLE |
| 68277Q105 | OKUR | ONKURE THERAPEUTICS INC | $6.8M | 4.44% | 2,839,674 | Common | SOLE |
| 23256X407 | HELP | CYBIN INC | $6.2M | 4.03% | 734,394 | Common | SOLE |
| 055477103 | BCAX | BICARA THERAPEUTICS | $6.0M | 3.91% | 643,382 | Common | SOLE |
| 74365U107 | TARA | PROTARA THERAPEUTICS INC | $5.3M | 3.47% | 1,752,115 | Common | SOLE |
| 14147L108 | CRDF | CARDIF ONCOLOGY INC | $4.4M | 2.90% | 1,408,767 | Common | SOLE |
| 05153U107 | AURA | AURA BIOSCIENCES INC | $3.7M | 2.44% | 595,744 | Common | SOLE |
| 92337C203 | VSTM | VERASTEM INC | $3.2M | 2.12% | 779,498 | Common | SOLE |
| 00032Q104 | WHWK | WHITEHAWK THERAPEUTICS INC | $2.1M | 1.39% | 1,139,363 | Common | SOLE |
| 09077B104 | BCABGBP | BIOATLA INC | $1.9M | 1.25% | 4,835,111 | Common | SOLE |
| G63365103 | MURA | MURAL ONCOLOGY PLC | $1.6M | 1.06% | 653,779 | Common | SOLE |
| 92941V308 | VYNE | VYNE THERAPEUTICS INC | $1.2M | 0.79% | 736,572 | Common | SOLE |
| 746964105 | QTTB | Q32 BIO INC. | $1.2M | 0.78% | 803,425 | Common | SOLE |
| 004890109 | ACRV | ACRIVON THERAPEUTICS INC | $482,232 | 0.32% | 405,237 | Common | SOLE |
| 98420X103 | ASNSUSD | X4 PHARMACEUTICALS INC | $292,087 | 0.19% | 153,730 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.